SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How SGP compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 6.1% | -4.2 pp | +5.6 pp | |
| LTM Jun 2026 | -3.2% | +2.4 pp | -7.2 pp | |
| LTM Apr 2026 | -7.2% | +18.2 pp | -47.5 pp | |
| LTM Jun 2026 | -30.7% | -9.3 pp | -1.9 pp | |
| LTM Mar 2026 | -36.6% | -19.8 pp | +107.3 pp | |
| LTM Mar 2026 | -46.8% | +16.4 pp | +71.2 pp | |
| LTM Mar 2026 | -558.2% | -235.2 pp | -375.2 pp | |
| LTM Mar 2026 | -3566.6% | -3304.7 pp | -492.4 pp | |
| LTM Mar 2026 | -18861.3% | — | — | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding SGP) | -36.6% | -6.7 pp | -4.6 pp | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.